AstraZeneca, GlaxoSmithKline, Merck: Emerging Markets Earnings Roundup (Part 2 of 3)

A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and other emerging markets and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.